Mitochondrial Agents for Bipolar Disorder
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background: Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit. Methods: This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review. Results: Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles. Conclusions: The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder's pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sepehrmanesh, Z., Kolahdooz, F., Abedi, F., Mazroii, N., Assarian, A., Asemi, Z., & Esmaillzadeh, A. (2016) · The Journal of Nutrition · doi:10.3945/jn.115.218883 · Cited by 143
RetractedFree Radicals, Antioxidants in Disease and Health
Department of Pharmacy, L. S. P. C. H., Pham-Huy, L. A., He, H., Department of Analytical Chemistry, C. P. U., Pham-Huyc, C., & Laboratory of Toxicology, F. O. P. (2008) · International Journal of Biomedical Science · doi:10.59566/ijbs.2008.4089 · Cited by 3,058 · cited 1×
“Vitamin E Vitamin E or tocopherol is a fat-soluble antioxidant, which has a stabilizing function in the mitochondrial membrane attributed to radical scavenging and lipid peroxidation reduction (Kagan et al., 1990; Pham-Huy et al., 2008).”
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 1×
“…et al., 2006), the treatment of bipolar depression is more challenging, as these agents may not improve depressive symptoms (Calabrese et al., 2007; Sachs et al., 2007), and treatment with antidepressants may induce phase switching, particularly with monotherapy (Post et al., 2006; Viktorin…”
Vitamin D deficiency and depression in adults: systematic review and meta-analysis
Anglin, R. E. S., Samaan, Z., Walter, S. D., & McDonald, S. D. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.106666 · Cited by 820
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013
Ferrari, A. J., Stockings, E., Khoo, J., Erskine, H. E., Degenhardt, L., Vos, T., & Whiteford, H. A. (2016) · Bipolar Disorders · doi:10.1111/bdi.12423 · Cited by 583
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557 · cited 1×
“Supplementary CoQ10 has poor oral bioavailability; however, it does cross the blood-brain barrier (Matthews et al., 1998).”
BackgroundBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationDirect antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448 · cited 1×
“Furthermore, creatine has been shown to have antioxidant properties in animal models of oxidative stress (Sullivan et al., 2000; Tarnopolsky and Beal, 2001; Lawler et al., 2002) A 4-week open-label trial with 10 participants experiencing treatment-resistant depression (8 unipolar and 2 bipolar) showed improved depress…”
BackgroundAndreazza, A. C., Shao, L., Wang, J.-F., & Young, L. T. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.22 · Cited by 448
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434 · cited 1×
“N-acetyl cysteine (NAC) is increasingly being used as an adjunctive therapy in psychiatry (Berk et al., 2013).”
Self-citationEnhancement of recovery from psychiatric illness by methylfolate
Godfrey, P. S. A., Toone, B. K., Bottiglien, T., Laundy, M., Reynolds, E. H., Carney, M. W. P., Flynn, T. G., & Chanarin, I. (1990) · The Lancet · doi:10.1016/0140-6736(90)91942-4 · Cited by 389
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3
Khan, N. A., Auranen, M., Paetau, I., Pirinen, E., Euro, L., Forsström, S., Pasila, L., Velagapudi, V., Carroll, C. J., Auwerx, J., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403943 · Cited by 385
Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., Suppes, T., McElroy, S., Keck, P. E., Denicoff, K. D., et al. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.013045 · Cited by 350
Coppen, A., & Bailey, J. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00153-1 · Cited by 337 · cited 5×
“…in depressed patients in another 2 placebocontrolled RCTs. Studies with samples of 127 and 42 patients with MDD, respectively, were treated with folic acid plus 20 mg of fluoxetine and showed greater improvement in the HAM-D and in the BDI (Coppen and Bailey, 2000; Venkatasubramanian et al., 2013).”
InfluentialPapakostas, G. I., Mischoulon, D., Shyu, I., Alpert, J. E., & Fava, M. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09081198 · Cited by 297
Shinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., Waichunas, D., Bumgarner, L., Bourdette, D., Silbert, L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130722 · Cited by 288
Bottiglieri, T. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.5.1151s · Cited by 286
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071114 · Cited by 275
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Judd, L. L., Schettler, P. J., Akiskal, H. S., Coryell, W., Leon, A. C., Maser, J. D., & Solomon, D. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.386 · Cited by 251
Viktorin, A., Lichtenstein, P., Thase, M. E., Larsson, H., Lundholm, C., Magnusson, P. K. E., & Landén, M. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111501 · Cited by 246 · cited 1×
“…the treatment of bipolar depression is more challenging, as these agents may not improve depressive symptoms (Calabrese et al., 2007; Sachs et al., 2007), and treatment with antidepressants may induce phase switching, particularly with monotherapy (Post et al., 2006; Viktorin et al., 2014).”
Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Perlis, R. H., Welge, J. A., Vornik, L. A., Hirschfeld, R. M. A., & Keck, P. E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0401 · Cited by 196 · cited 1×
“Current pharmacological treatment offers limited efficacy overall, either in preventing relapses or recovery from acute episodes of depression (Perlis et al., 2006).”
BackgroundAlpha-lipoic acid as a new treatment option for Azheimer type dementia
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00104-2 · Cited by 188
Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Self-citationOxidative stress in early stage Bipolar Disorder and the association with response to lithium
de Sousa, R. T., Zarate, C. A., Zanetti, M. V., Costa, A. C., Talib, L. L., Gattaz, W. F., & Machado-Vieira, R. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.11.011 · Cited by 169
Walker, J. G., Batterham, P. J., Mackinnon, A. J., Jorm, A. F., Hickie, I., Fenech, M., Kljakovic, M., Crisp, D., & Christensen, H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.007799 · Cited by 165
CASS, W. A., SMITH, M. P., & PETERS, L. E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.023 · Cited by 149
Lyoo, I. K., Kong, S. W., Sung, S. M., Hirashima, F., Parow, A., Hennen, J., Cohen, B. M., & Renshaw, P. F. (2003) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(03)00046-5 · Cited by 140
Creatine monohydrate in resistant depression: A preliminary study
Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00532.x · Cited by 118
Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96 · cited 8×
“Relevant to mitochondrial physiology, melatonin improves oxidative phosphorylation, increasing the activity of the I and IV dose-dependent complexes and membrane fluidity and closes the mitochondrial permeability transition pore (a protein complex spanning the inner and outer mitochondrial membranes), preventing ATP d…”
InfluentialSelf-citationFornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67 · cited 1×
“There were 4 drop-outs in total due to polarity change (1 manic and 3 hypomanic episodes) (Fornaro et al., 2013).”
Effects of N‐acetyl cysteine on cognitive function in bipolar disorder
Dean, O. M., Bush, A. I., Copolov, D. L., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson‐Hunt, M., & Berk, M. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02392.x · Cited by 58 · cited 28×
“A protocol has been published describing a study of NAC and a combination of other agents that enhance mitochondrial function, compared with placebo, over 16 weeks of treatment (Dean et al., 2015).”
BackgroundInfluentialSelf-citationA preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania
Vieira da Silva Magalhães, P., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413481631 · Cited by 58 · cited 1×
“The investigation of those experiencing mania indicated withingroup improvements in the NAC group (Magalhães et al., 2013).”
BackgroundSelf-citationZandi, P. P. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.82 · Cited by 47
Lyoo, I. K., Demopulos, C. M., Hirashima, F., Ahn, K. H., & Renshaw, P. F. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00041.x · Cited by 33
Cited by
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
“An increasing number of agents capable of enhancing antioxidant defenses or mitochondrial functioning have recently been studied for the treatment of mood disorders, which could also be worth considering as adjuvant therapy to current pharmacological treatments for NAFLD [71].”
BackgroundSelf-citationMitochondria, Microglia, and the Immune System—How Are They Linked in Affective Disorders?
Culmsee, C., Michels, S., Scheu, S., Arolt, V., Dannlowski, U., & Alferink, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00739 · Cited by 110
Contribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations
Sun, D., Wei, Y., Zheng, H.-X., Jin, L., & Wang, J. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00128 · Cited by 21
“, 2016) and mitochondrial dysfunction (Dolle et al., 2016; Pera et al., 2017; Ehrnhoefer et al., 2018; Lindqvist et al., 2018; Pereira et al., 2018; Puthumana and Regenold, 2019) have long been reported as pathogenic in psychiatric and neurodegenerative diseases.”
Background
Metadata
- Authors
- Pereira, C., Chavarria, V., Vian, J., Ashton, M. M., Berk, M., Marx, W., & Dean, O. M.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-03-27
- Volume
- 21
- Issue
- 6
- Pages
- 550-569
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2795365279
- Cited by
- 40
- References
- 40
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.